semaglutide mastery course
Unit 9 of 12

dosing and administration

titration schedules, routes, reconstitution, and community protocols

dosing and administration

This unit documents the FDA-approved titration schedules for Ozempic, Wegovy, and Rybelsus alongside community-reported dosing protocols, all presented for educational purposes only. Semaglutide requires a slow dose escalation to build GI tolerance, and the differences between formulations matter clinically. All dosing decisions should be made with a licensed healthcare provider.

Semaglutide is available in subcutaneous and oral formulations, each with distinct titration ramps, bioavailability profiles, and practical considerations. This unit covers the FDA-approved titration schedules for Ozempic, Wegovy, and Rybelsus alongside community-reported protocols for compounded formulations.

The paid sections lay out the full Ozempic, Wegovy, and Rybelsus titration ladders side by side, injection technique and site rotation, community split-dosing patterns, and the reconstitution math for compounded vials -- including the salt-form confusion that has driven most reported overdoses.

Interactive Visualization

explore titration schedules and calculate dose timing across approved and community protocols.

titration schedule and dose calculator
0.25 mg
starting dose for both Ozempic and Wegovy -- sub-therapeutic, designed purely for GI tract adaptation before escalation
2.4 mg
maximum approved weekly dose (Wegovy maintenance) -- reached after a 16-week, 5-step titration schedule
~168 h
elimination half-life enabling once-weekly dosing -- albumin binding via the C18 fatty diacid chain keeps steady-state levels stable between injections
520+
adverse events reported to FDA from compounded semaglutide -- salt form confusion (base vs sodium) drove many 5-20x overdoses
salt form confusion risk. Compounded semaglutide vials may contain semaglutide sodium or semaglutide acetate instead of semaglutide base. These salt forms have different molecular weights, meaning a vial labeled "5 mg semaglutide" may deliver a different peptide dose depending on the form. This mismatch has caused 5-20x overdoses and is the single most dangerous error in compounded semaglutide use.

key terms for this unit

T titration clinical pharmacology
The process of gradually increasing dose to reach a therapeutic level while minimizing side effects. Semaglutide's titration exists because skipping steps is the most common cause of severe GI intolerance. Wegovy has 5 steps over 16 weeks; Ozempic has 4; Rybelsus has 3.
S SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) oral formulation
The absorption enhancer that makes oral semaglutide (Rybelsus) possible. SNAC creates a localized pH buffer at the gastric mucosal surface, temporarily increasing peptide permeability. This is why Rybelsus must be taken with exactly 4 oz of water on an empty stomach -- more water dilutes the SNAC microenvironment.
B bacteriostatic water (BAC water) compounding
Sterile water containing 0.9% benzyl alcohol as a preservative, used to reconstitute lyophilized peptide vials. The reconstitution volume determines concentration (mg/mL), which in turn determines injection volume for each dose. Accurate insulin syringes (U-100) are required for measurement.
L lipohypertrophy injection technique
Fatty lumps that develop at repeated injection sites, impairing drug absorption and producing erratic pharmacokinetics. Prevented by rotating injection sites within the abdomen, thigh, or upper arm each week. A common cause of unexplained efficacy loss in patients who inject in the same spot.
S split dosing community protocols
A community-reported practice of dividing the weekly dose into 2+ injections (e.g., 0.5 mg twice weekly instead of 1.0 mg once weekly). Theoretical rationale is lower peak concentrations reducing nausea. Not studied in controlled trials, and semaglutide's long half-life may make the effect minimal.